Abstract
CSF1R is a receptor tyrosine kinase responsible for the growth/survival/polarization of macrophages and overexpressed in some AML patients. We hypothesized that a novel multi-kinase inhibitor (TKi), narazaciclib (HX301/ON123300), with high potency against CSF1R ($IC_{50}$ ~ 0.285 nM), would have anti-AML effects. We tested this by confirming HX301's high potency against CSF1R ($IC_{50}$ ~ 0.285 nM), as well as other kinases, e.g. FLT3 ($IC_{50}$ of ~ 19.77 nM) and CDK6 (0.53 nM). An in vitro proliferation assay showed that narazaciclib has a high growth inhibitory effect in cell cultures where CSF1R or mutant FLT3-ITD variants that may be proliferation drivers, including primary macrophages ($IC_{50}$ of 72.5 nM) and a subset of AML lines ($IC_{50} < 1.5$ μM). In vivo pharmacology modeling of narazaciclib using five AML xenografts resulted in: inhibition of MV4-11 (FLT3-ITD) subcutaneous tumor growth and complete suppression of AM7577-PDX (FLT3-ITD/CSF1R$^{med}$) systemic growth, likely due to the suppression of FLT3-ITD activity; complete suppression of AM8096-PDX (CSF1R$^{hi}$/wild-type FLT3) growth, likely due to the inhibition of CSF1R ("a putative driver"); and nonresponse of both AM5512-PDX and AM7407-PDX (wild-type FLT3/CSF1R$^{lo}$). Significant leukemia load reductions in bone marrow, where disease originated, were also achieved in both responders (AM7577/AM8096), implicating that HX301 might be a potentially more effective therapy than those only affecting peripheral leukemic cells. Altogether, narazaciclib can potentially be a candidate treatment for a subset of AML with CSF1R$^{hi}$ and/or mutant FLT3-ITD variants, particularly second generation FLT3 inhibitor resistant variants.
Introduction
Acute Myeloid Leukemia (AML) is a highly aggressive blood cancer characterized by a high relapse rate (33–78%), largely attributed to leukemia-initiating cells (LICs) that find sanctuary in the bone marrow. While targeted therapies focusing on FLT3 mutations have improved outcomes, patients frequently develop secondary resistance mutations, such as the F691L "gatekeeper" mutation. Furthermore, alternative drivers like CDK6 and CSF1R contribute to disease progression. This study introduces Narazaciclib (HX301/ON123300) as a next-generation multi-kinase inhibitor designed to overcome these resistance mechanisms by simultaneously targeting CSF1R, FLT3, and CDK6.
Methods
The researchers employed a comprehensive preclinical approach, including kinase potency assays to measure $IC_{50}$ against purified proteins and screening across a panel of 33 AML cell lines. Molecular profiling via RNAseq and Whole Exome Sequencing (WES) was used to identify genetic markers of response. Finally, the drug's efficacy was tested in five systemic Patient-Derived Xenograft (PDX) models (AM7577, AM8096, AM5512, AM7407, and MV4-11), representing diverse genetic subtypes of AML, to evaluate leukemia load reduction in the blood, spleen, and bone marrow.
Results
Potency and Biomarker Identification
Narazaciclib demonstrated sub-nanomolar potency against CSF1R ($IC_{50} \approx 0.285$ nM) and CDK6 (0.53 nM). In cell line screenings, 15 out of 33 AML lines were sensitive, with a notable 100% response rate in lines carrying the FLT3-ITD mutation. Analysis of mRNA expression revealed that high levels of CSF1R significantly correlated with drug sensitivity, establishing it as a potential biomarker for patient selection.
In Vivo Efficacy in PDX Models
In vivo studies confirmed the drug's ability to penetrate the bone marrow and clear leukemic cells. In the AM8096 PDX model, which exhibits high CSF1R expression, Narazaciclib achieved 97.83% tumor growth inhibition. Conversely, models with low CSF1R expression and wild-type FLT3, such as AM5512 and AM7407, did not respond to treatment, further validating the role of CSF1R as a driver and biomarker.
Overcoming Resistance
Narazaciclib showed superior potency against several resistant FLT3 mutations, including D835Y and F691L, compared to wild-type FLT3. This suggests its potential as a powerful second-line treatment for patients who have failed current FLT3 inhibitors. Additionally, combining Narazaciclib with the standard-of-care drug Azacitidine demonstrated synergistic anti-leukemic activity.
Discussion and Conclusion
Narazaciclib's multi-pronged attack on CSF1R, FLT3, and CDK6 addresses the complexity of AML and its resistance mechanisms. By targeting both the leukemic cells and the supportive bone marrow microenvironment, it offers a more comprehensive therapeutic approach than single-target inhibitors. While some sensitivity was observed in lines with low levels of primary targets—possibly due to inhibition of other kinases like SIK-3—the drug's efficacy in CSF1R-high and FLT3-ITD models is clear. Narazaciclib is currently undergoing early-stage clinical trials (NCT05731934) to evaluate its safety and efficacy in human patients.
Summary updated